Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Company Deals

MediTrust Mabwell Insurance Ecosystem Partnership

Fineline Cube Feb 5, 2026
Company Deals

Pfizer Launches Migraine Management Zone at China Pharmacy

Fineline Cube Feb 5, 2026
Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026
Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026
Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026
Company Drug

Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors

Fineline Cube Feb 5, 2026
Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Fineline Cube Feb 5, 2026
Company Deals Drug

Northeast Pharma Licenses MedAbome’s MAb11-22.1 for ADC and CAR-T Development

Fineline Cube Sep 5, 2022

China’s Northeast Pharmaceutical Co., Ltd (SHE: 000597) has signed a licensing agreement with U.S.-based MedAbome...

Company Drug

Alphamab Oncology Highlights KN046, KN026 Advances at ESMO 2022

Fineline Cube Sep 5, 2022

China’s Alphamab Oncology (HKG: 9966) will present updated clinical data for its bispecific antibody candidates...

Company Drug

AstraZeneca’s Farxiga Wins China Approval for Chronic Kidney Disease

Fineline Cube Sep 5, 2022

UK pharma giant AstraZeneca (AZ, NASDAQ: AZN) announced a new approval for Farxiga (dapagliflozin), its...

Company Drug

Innovent Biologics Doses First Patient in Higher-Dose Mazdutide Obesity Trial

Fineline Cube Sep 5, 2022

China’s Innovent Biologics, Inc. (HKG: 1801) announced that the first participant has been dosed in...

Company Drug

Shanghai Pharma’s CD20 Antibody Advances to Primary Nephropathy Trial After NMPA Approval

Fineline Cube Sep 5, 2022

China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products...

Company Drug

Walvax Biotech Wins NMPA Approval for mRNA and Recombinant COVID-19 Vaccines

Fineline Cube Sep 2, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has received clinical trial approvals from the National...

Company Deals

Medim Science Raises Funds for Macrophage-Targeting Biologics in Cancer Therapy

Fineline Cube Sep 2, 2022

Hangzhou-based Medim Science, China’s first pharma firm focused on macrophage-targeting biologics, has reportedly raised tens...

Drug Medical Device

China’s Pharmaceutical Industry Sees Revenue Decline Amid Export Shifts

Fineline Cube Sep 2, 2022

China’s pharmaceutical manufacturing sector reported a 1.8% year-on-year (YOY) revenue decline to RMB 1.6 trillion...

Company Deals

Tibet Duo Rui and Nanjing Heron Forge Pharmaceutical Collaboration in China

Fineline Cube Sep 2, 2022

China-based Tibet Duo Rui Pharmaceutical Co., Ltd and Nanjing Heron Pharmaceutical Science and Technology Co.,...

Company Drug

CARsgen Therapeutics Launches GMP Manufacturing for CAR-T Cell Therapies in North Carolina

Fineline Cube Sep 2, 2022

China’s CARsgen Therapeutics Holdings Ltd (HKG: 2171), a chimeric antigen receptor (CAR)-T cell specialist, has...

Company Deals

MegaRobo and Danaher Life Sciences Partner on Lab Automation in China

Fineline Cube Sep 2, 2022

Beijing-based MegaRobo Technologies, a robotics and AI firm in life sciences, has partnered with Danaher...

Company Drug

Hengrui Medicine’s HRG2101 Inhaler Wins NMPA Approval for IPF Clinical Trial

Fineline Cube Sep 2, 2022

China’s Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received approval from the National Medical...

Company Deals

U Protech Secures Angel Financing for PROTAC and Molecular Glue Drug Pipeline

Fineline Cube Sep 2, 2022

U Protech, a Hangzhou-based biotech focused on next-generation protein degradation therapies, has raised tens of...

Company Deals Digital

J&J China, Tencent Launch Digital Rhinitis Platform “Love Nose e-Station”

Fineline Cube Sep 2, 2022

Johnson & Johnson’s (J&J, NYSE: JNJ) J&J China Self Care and China’s Tencent have launched...

Company Deals

Neukio Biotherapeutics Completes USD 50M Series A-1 Financing for iPSC-CAR-NK Therapy

Fineline Cube Sep 2, 2022

Shanghai-based Neukio Biotherapeutics, a developer of iPSC-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies,...

Company Deals

Acorda Therapeutics Licenses Preclinical Drug Nepicastat to China’s Asieris

Fineline Cube Sep 2, 2022

US-based Acorda Therapeutics Inc. (Nasdaq: ACOR) announced a licensing agreement with China’s Asieris Pharmaceuticals for...

Policy / Regulatory

SAMR Issues New Rules for Online Drug Sales in China

Fineline Cube Sep 2, 2022

China’s State Administration for Market Regulation (SAMR) has released the “Measures for the Supervision and...

Policy / Regulatory

NMPA Designates Shijiazhuang Airport as Drug Import Port for Narcotics, Psychotropics

Fineline Cube Sep 2, 2022

China’s National Medical Products Administration (NMPA) has designated Shijiazhuang Airport in Hebei Province as an...

Company

Henlius Biotech Plans US Bridging Study for Serplulimab in ES-SCLC

Fineline Cube Sep 1, 2022

Shanghai Henlius Biotech (HKG: 2696) is advancing its checkpoint inhibitor serplulimab toward the U.S. market,...

Company Drug

RedCloud Bio Doses First Patient in H002 EGFR TKI Phase I/IIa Trial for NSCLC

Fineline Cube Sep 1, 2022

Shanghai-based RedCloud Bio announced that the first patient has been dosed in a Phase I/IIa...

Posts pagination

1 … 583 584 585 … 620

Recent updates

  • Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
  • Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
  • Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal
  • GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength
  • MediTrust Mabwell Insurance Ecosystem Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength

Company

Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Company Medical Device

GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.